CTLA4 and obstructive sleep apnea syndrome: To predict the immunotherapy response for each patient with OSA, we subsequently conducted SubMap analysis with an OSA cohort which included both patients receiving and not receiving anti-PD-1 or anti-CTLA4 therapy.